NASDAQ:VYGR - Voyager Therapeutics Stock Price, News, & Analysis

$25.15
-0.65 (-2.52 %)
(As of 06/26/2019 01:48 PM ET)
Today's Range
$25.15
Now: $25.15
$26.01
50-Day Range
$21.20
MA: $24.02
$28.2133
52-Week Range
$7.76
Now: $25.15
$28.79
Volume9,336 shs
Average Volume555,140 shs
Market Capitalization$926.27 million
P/E RatioN/A
Dividend YieldN/A
Beta2.49
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD101 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and VY-NAV01 for severe chronic pain. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VYGR
CUSIPN/A
Phone857-259-5340

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.62 million
Book Value$1.43 per share

Profitability

Net Income$-88,290,000.00
Net Margins-804.55%

Miscellaneous

Employees123
Market Cap$926.27 million
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable

Receive VYGR News and Ratings via Email

Sign-up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.

Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics Inc (NASDAQ:VYGR) posted its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of $0.65 by $1.46. The company earned $5.20 million during the quarter, compared to analyst estimates of $3 million. Voyager Therapeutics had a negative net margin of 804.55% and a negative return on equity of 129.67%. View Voyager Therapeutics' Earnings History.

When is Voyager Therapeutics' next earnings date?

Voyager Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Voyager Therapeutics.

What price target have analysts set for VYGR?

10 brokers have issued 1-year price targets for Voyager Therapeutics' stock. Their forecasts range from $13.00 to $37.00. On average, they expect Voyager Therapeutics' share price to reach $27.00 in the next twelve months. This suggests a possible upside of 7.4% from the stock's current price. View Analyst Price Targets for Voyager Therapeutics.

What is the consensus analysts' recommendation for Voyager Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Voyager Therapeutics.

What are Wall Street analysts saying about Voyager Therapeutics stock?

Here are some recent quotes from research analysts about Voyager Therapeutics stock:
  • 1. HC Wainwright analysts commented, "With the stock above our $22 price target, we await progress from its other pipeline initiatives including potential IND clearance to make adjustments to our model." (5/6/2019)
  • 2. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (3/2/2019)

Has Voyager Therapeutics been receiving favorable news coverage?

Headlines about VYGR stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Voyager Therapeutics earned a news sentiment score of 1.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for Voyager Therapeutics.

Who are some of Voyager Therapeutics' key competitors?

What other stocks do shareholders of Voyager Therapeutics own?

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the folowing people:
  • Mr. Matthew P. Ottmer, Chief Operating Officer (Age 48)
  • Dr. Steven M. Paul, Exec. Science Advisor & Director (Age 68)
  • Mr. G. Andre Turenne, CEO, Pres & Director
  • Dr. Krystof Bankiewicz M.D., Ph.D., Founder
  • Dr. Guangping Gao Ph.D., Founder

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (2.00%), Clearbridge Investments LLC (1.03%), JPMorgan Chase & Co. (0.69%), Raymond James Financial Services Advisors Inc. (0.55%), Spark Investment Management LLC (0.40%) and Alps Advisors Inc. (0.21%). Company insiders that own Voyager Therapeutics stock include Bernard Ravina, Dinah PhD Sah, Glenn Pierce, James A Geraghty, Jane Henderson and Neurocrine Biosciences Inc. View Institutional Ownership Trends for Voyager Therapeutics.

Which major investors are selling Voyager Therapeutics stock?

VYGR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, JPMorgan Chase & Co., Aevitas Wealth Management Inc., Birchview Capital LP, Nisa Investment Advisors LLC and Patriot Financial Group Insurance Agency LLC. View Insider Buying and Selling for Voyager Therapeutics.

Which major investors are buying Voyager Therapeutics stock?

VYGR stock was acquired by a variety of institutional investors in the last quarter, including Clearbridge Investments LLC, Spark Investment Management LLC, Raymond James Financial Services Advisors Inc., Algert Global LLC, SG Americas Securities LLC, BNP Paribas Arbitrage SA, Alps Advisors Inc. and SG3 Management LLC. Company insiders that have bought Voyager Therapeutics stock in the last two years include Glenn Pierce, James A Geraghty and Neurocrine Biosciences Inc. View Insider Buying and Selling for Voyager Therapeutics.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $25.15.

How big of a company is Voyager Therapeutics?

Voyager Therapeutics has a market capitalization of $926.27 million and generates $7.62 million in revenue each year. The company earns $-88,290,000.00 in net income (profit) each year or ($2.75) on an earnings per share basis. Voyager Therapeutics employs 123 workers across the globe.View Additional Information About Voyager Therapeutics.

What is Voyager Therapeutics' official website?

The official website for Voyager Therapeutics is http://www.voyagertherapeutics.com/.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-5340 or via email at [email protected]


MarketBeat Community Rating for Voyager Therapeutics (NASDAQ VYGR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  286 (Vote Outperform)
Underperform Votes:  231 (Vote Underperform)
Total Votes:  517
MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote "Outperform" if you believe VYGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VYGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel